Soligenix, Inc.

Soligenix, Inc., a biopharmaceutical firm in its advanced development stages, concentrates on bringing innovative products to market within the United States, specifically targeting rare illnesses. The company's operations are divided into two main divisions: Specialized BioTherapeutics and Public Health Solutions. Within the Specialized BioTherapeutics division, Soligenix is advancing SGX301 (marketed as HyBryte), a novel photodynamic treatment that has successfully completed its Phase III clinical trials for managing cutaneous T-cell lymphoma. This segment also includes SGX942, an innate defense regulator technology currently undergoing Phase III trials for various inflammatory conditions, notably oral mucositis in patients with head and neck cancer. Additionally, this division is pursuing proprietary oral formulations of beclomethasone 17,21-dipropionate designed to prevent or treat severe inflammatory gastrointestinal disorders, such as SGX203 for pediatric Crohn's disease. Another candidate, SGX302, is currently in Phase I/II clinical development for addressing mild-to-moderate psoriasis. The Public Health Solutions segment is dedicated to developing several critical assets. These include RiVax, a vaccine candidate against ricin toxin, which has successfully completed Phase Ia and Ib clinical evaluations; SGX943, a therapeutic agent in pre-clinical studies aimed at combating antibiotic-resistant and emerging infectious diseases; ThermoVax, an early-stage technology focused on enhancing vaccine thermostability; and CiVax, a pre-clinical vaccine candidate intended for COVID-19 prevention. Soligenix, Inc. was originally established as DOR BioPharma, Inc. before adopting its current name in 2009. Founded in 1987, the company maintains its corporate headquarters in Princeton, New Jersey.

業界

Biotechnology

セクター

Healthcare

本社

US

最高経営責任者（CEO）

Christopher J. Schaber

上場以来

1994年4月4日

従業員

14